Updates in pharmacotherapy of obesity
Obesity is now recognized as a chronic, progressive condition requiring early intervention and long-term management to achieve health benefits and improve metabolic risk factors. The main objective of obesity pharmacotherapy is weight loss and weight loss maintenance. There is increasing acceptance...
Gespeichert in:
| Veröffentlicht in: | Journal of the National Medical Association 2024-10, Vol.116 (5), p.576-587 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 587 |
|---|---|
| container_issue | 5 |
| container_start_page | 576 |
| container_title | Journal of the National Medical Association |
| container_volume | 116 |
| creator | Ogunsakin, Amie A. Olakunde, Tomilola I. Fehintola, Moses D. Malmberg, Ifeoluwa Olakunde, Akinwale Dokun, Ayotunde O. |
| description | Obesity is now recognized as a chronic, progressive condition requiring early intervention and long-term management to achieve health benefits and improve metabolic risk factors. The main objective of obesity pharmacotherapy is weight loss and weight loss maintenance. There is increasing acceptance of anti-obesity medications as an adjunct to lifestyle modifications and/or surgery. In recent years there has been an evolution in management approach and pharmacologic options for treatment. As a result, there is increased focus on the efficacy and safety of these agents. We provide a historical perspective, review of recent studies on anti-obesity medication outcomes showing efficacy, potential side effects and promising therapies in development. |
| doi_str_mv | 10.1016/j.jnma.2024.09.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3122641629</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0027968424002050</els_id><sourcerecordid>3122641629</sourcerecordid><originalsourceid>FETCH-LOGICAL-c237t-bb8c31ba70c83a216201a26fe51a5a4b984a08c6a789b998fbecb28e74f888ce3</originalsourceid><addsrcrecordid>eNp9kEtLAzEURoMoWqt_wIXMRnAzY16TB7iR4gsKbuw6JJk7NEPnYTIV-u-d0urS1d2c78A9CN0QXBBMxENTNF1rC4opL7AuMOYnaEY0ZzkXmp2iGcZU5loofoEuU2owxkqX5Tm6YJpLKQWdobvVUNkRUha6bFjb2Frfj2uIdthlfZ31DlIYd1forLabBNfHO0erl-fPxVu-_Hh9Xzwtc0-ZHHPnlGfEWYm9YpYSQTGxVNRQElta7rTiFisvrFTaaa1qB95RBZLXSikPbI7uD94h9l9bSKNpQ_Kw2dgO-m0yjFAq-OTVE0oPqI99ShFqM8TQ2rgzBJt9HtOYfR6zz2OwNlOeaXR79G9dC9Xf5LfHBDweAJi-_A4QTfIBOg9ViOBHU_XhP_8PeF51Vg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3122641629</pqid></control><display><type>article</type><title>Updates in pharmacotherapy of obesity</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ogunsakin, Amie A. ; Olakunde, Tomilola I. ; Fehintola, Moses D. ; Malmberg, Ifeoluwa ; Olakunde, Akinwale ; Dokun, Ayotunde O.</creator><creatorcontrib>Ogunsakin, Amie A. ; Olakunde, Tomilola I. ; Fehintola, Moses D. ; Malmberg, Ifeoluwa ; Olakunde, Akinwale ; Dokun, Ayotunde O.</creatorcontrib><description>Obesity is now recognized as a chronic, progressive condition requiring early intervention and long-term management to achieve health benefits and improve metabolic risk factors. The main objective of obesity pharmacotherapy is weight loss and weight loss maintenance. There is increasing acceptance of anti-obesity medications as an adjunct to lifestyle modifications and/or surgery. In recent years there has been an evolution in management approach and pharmacologic options for treatment. As a result, there is increased focus on the efficacy and safety of these agents. We provide a historical perspective, review of recent studies on anti-obesity medication outcomes showing efficacy, potential side effects and promising therapies in development.</description><identifier>ISSN: 0027-9684</identifier><identifier>ISSN: 1943-4693</identifier><identifier>EISSN: 1943-4693</identifier><identifier>DOI: 10.1016/j.jnma.2024.09.004</identifier><identifier>PMID: 39477762</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Anti-obesity ; Anti-obesity agents ; Anti-Obesity Agents - administration & dosage ; Anti-Obesity Agents - adverse effects ; Anti-Obesity Agents - history ; Humans ; Obesity ; Obesity - drug therapy ; Pediatric ; Pharmaceutical ; Pharmacotherapy ; Weight Loss - drug effects</subject><ispartof>Journal of the National Medical Association, 2024-10, Vol.116 (5), p.576-587</ispartof><rights>2024 National Medical Association</rights><rights>Copyright © 2024 National Medical Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c237t-bb8c31ba70c83a216201a26fe51a5a4b984a08c6a789b998fbecb28e74f888ce3</cites><orcidid>0000-0002-0838-3849 ; 0009-0007-7488-1532 ; 0009-0003-2779-6053 ; 0009-0002-3114-7390 ; 0000-0002-9003-0048</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39477762$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ogunsakin, Amie A.</creatorcontrib><creatorcontrib>Olakunde, Tomilola I.</creatorcontrib><creatorcontrib>Fehintola, Moses D.</creatorcontrib><creatorcontrib>Malmberg, Ifeoluwa</creatorcontrib><creatorcontrib>Olakunde, Akinwale</creatorcontrib><creatorcontrib>Dokun, Ayotunde O.</creatorcontrib><title>Updates in pharmacotherapy of obesity</title><title>Journal of the National Medical Association</title><addtitle>J Natl Med Assoc</addtitle><description>Obesity is now recognized as a chronic, progressive condition requiring early intervention and long-term management to achieve health benefits and improve metabolic risk factors. The main objective of obesity pharmacotherapy is weight loss and weight loss maintenance. There is increasing acceptance of anti-obesity medications as an adjunct to lifestyle modifications and/or surgery. In recent years there has been an evolution in management approach and pharmacologic options for treatment. As a result, there is increased focus on the efficacy and safety of these agents. We provide a historical perspective, review of recent studies on anti-obesity medication outcomes showing efficacy, potential side effects and promising therapies in development.</description><subject>Anti-obesity</subject><subject>Anti-obesity agents</subject><subject>Anti-Obesity Agents - administration & dosage</subject><subject>Anti-Obesity Agents - adverse effects</subject><subject>Anti-Obesity Agents - history</subject><subject>Humans</subject><subject>Obesity</subject><subject>Obesity - drug therapy</subject><subject>Pediatric</subject><subject>Pharmaceutical</subject><subject>Pharmacotherapy</subject><subject>Weight Loss - drug effects</subject><issn>0027-9684</issn><issn>1943-4693</issn><issn>1943-4693</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLAzEURoMoWqt_wIXMRnAzY16TB7iR4gsKbuw6JJk7NEPnYTIV-u-d0urS1d2c78A9CN0QXBBMxENTNF1rC4opL7AuMOYnaEY0ZzkXmp2iGcZU5loofoEuU2owxkqX5Tm6YJpLKQWdobvVUNkRUha6bFjb2Frfj2uIdthlfZ31DlIYd1forLabBNfHO0erl-fPxVu-_Hh9Xzwtc0-ZHHPnlGfEWYm9YpYSQTGxVNRQElta7rTiFisvrFTaaa1qB95RBZLXSikPbI7uD94h9l9bSKNpQ_Kw2dgO-m0yjFAq-OTVE0oPqI99ShFqM8TQ2rgzBJt9HtOYfR6zz2OwNlOeaXR79G9dC9Xf5LfHBDweAJi-_A4QTfIBOg9ViOBHU_XhP_8PeF51Vg</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Ogunsakin, Amie A.</creator><creator>Olakunde, Tomilola I.</creator><creator>Fehintola, Moses D.</creator><creator>Malmberg, Ifeoluwa</creator><creator>Olakunde, Akinwale</creator><creator>Dokun, Ayotunde O.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0838-3849</orcidid><orcidid>https://orcid.org/0009-0007-7488-1532</orcidid><orcidid>https://orcid.org/0009-0003-2779-6053</orcidid><orcidid>https://orcid.org/0009-0002-3114-7390</orcidid><orcidid>https://orcid.org/0000-0002-9003-0048</orcidid></search><sort><creationdate>202410</creationdate><title>Updates in pharmacotherapy of obesity</title><author>Ogunsakin, Amie A. ; Olakunde, Tomilola I. ; Fehintola, Moses D. ; Malmberg, Ifeoluwa ; Olakunde, Akinwale ; Dokun, Ayotunde O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c237t-bb8c31ba70c83a216201a26fe51a5a4b984a08c6a789b998fbecb28e74f888ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Anti-obesity</topic><topic>Anti-obesity agents</topic><topic>Anti-Obesity Agents - administration & dosage</topic><topic>Anti-Obesity Agents - adverse effects</topic><topic>Anti-Obesity Agents - history</topic><topic>Humans</topic><topic>Obesity</topic><topic>Obesity - drug therapy</topic><topic>Pediatric</topic><topic>Pharmaceutical</topic><topic>Pharmacotherapy</topic><topic>Weight Loss - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ogunsakin, Amie A.</creatorcontrib><creatorcontrib>Olakunde, Tomilola I.</creatorcontrib><creatorcontrib>Fehintola, Moses D.</creatorcontrib><creatorcontrib>Malmberg, Ifeoluwa</creatorcontrib><creatorcontrib>Olakunde, Akinwale</creatorcontrib><creatorcontrib>Dokun, Ayotunde O.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the National Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ogunsakin, Amie A.</au><au>Olakunde, Tomilola I.</au><au>Fehintola, Moses D.</au><au>Malmberg, Ifeoluwa</au><au>Olakunde, Akinwale</au><au>Dokun, Ayotunde O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Updates in pharmacotherapy of obesity</atitle><jtitle>Journal of the National Medical Association</jtitle><addtitle>J Natl Med Assoc</addtitle><date>2024-10</date><risdate>2024</risdate><volume>116</volume><issue>5</issue><spage>576</spage><epage>587</epage><pages>576-587</pages><issn>0027-9684</issn><issn>1943-4693</issn><eissn>1943-4693</eissn><abstract>Obesity is now recognized as a chronic, progressive condition requiring early intervention and long-term management to achieve health benefits and improve metabolic risk factors. The main objective of obesity pharmacotherapy is weight loss and weight loss maintenance. There is increasing acceptance of anti-obesity medications as an adjunct to lifestyle modifications and/or surgery. In recent years there has been an evolution in management approach and pharmacologic options for treatment. As a result, there is increased focus on the efficacy and safety of these agents. We provide a historical perspective, review of recent studies on anti-obesity medication outcomes showing efficacy, potential side effects and promising therapies in development.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39477762</pmid><doi>10.1016/j.jnma.2024.09.004</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-0838-3849</orcidid><orcidid>https://orcid.org/0009-0007-7488-1532</orcidid><orcidid>https://orcid.org/0009-0003-2779-6053</orcidid><orcidid>https://orcid.org/0009-0002-3114-7390</orcidid><orcidid>https://orcid.org/0000-0002-9003-0048</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0027-9684 |
| ispartof | Journal of the National Medical Association, 2024-10, Vol.116 (5), p.576-587 |
| issn | 0027-9684 1943-4693 1943-4693 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3122641629 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Anti-obesity Anti-obesity agents Anti-Obesity Agents - administration & dosage Anti-Obesity Agents - adverse effects Anti-Obesity Agents - history Humans Obesity Obesity - drug therapy Pediatric Pharmaceutical Pharmacotherapy Weight Loss - drug effects |
| title | Updates in pharmacotherapy of obesity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T06%3A41%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Updates%20in%20pharmacotherapy%20of%20obesity&rft.jtitle=Journal%20of%20the%20National%20Medical%20Association&rft.au=Ogunsakin,%20Amie%20A.&rft.date=2024-10&rft.volume=116&rft.issue=5&rft.spage=576&rft.epage=587&rft.pages=576-587&rft.issn=0027-9684&rft.eissn=1943-4693&rft_id=info:doi/10.1016/j.jnma.2024.09.004&rft_dat=%3Cproquest_cross%3E3122641629%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3122641629&rft_id=info:pmid/39477762&rft_els_id=S0027968424002050&rfr_iscdi=true |